The most effective reversible forms of birth control are mostly priced out of reach for millions of women who need it most—until now. An unusual partnership between a nonprofit pharmaceutical company and a traditional pharmaceutical distributor aims to increase access to IUDs (intrauterine devices) for U.S. servicewomen and in public clinics.
Liletta, a hormonal IUD approved by the FDA in April 2015, resulted from a joint venture between Allergan AGN +0.72% and Medicines360, a global nonprofit women’s health pharmaceutical company whose primary funding comes from an anonymous donor’s grant.
